Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer
NCT03900884Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in breast cancer, sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Maximum Tolerated Dose at 36 months, Dose-Limiting Toxicities at 36 months and 1 more. Started Sep 2019; status: completed.
02
Drugs
venetoclax
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03900884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900884.